4/A: Processa Pharmaceuticals Executive David Young Reports Beneficial Ownership Changes

David Young, President of Research & Development at Processa Pharmaceuticals, files an amendment to a previous Form 4, detailing changes in his beneficial ownership of company stock and warrants.

Summary

• David Young, the President of Research & Development at Processa Pharmaceuticals, filed an amended Form 4 with the SEC.
• The form details changes in his beneficial ownership of Processa Pharmaceuticals stock and warrants.
• The earliest transaction date reported is January 27, 2025, and the amendment was filed on February 18, 2025, correcting a previous filing from January 29, 2025.
• Young directly owns 205,405 shares of common stock.
• He indirectly owns 30,985 shares through the Young-Plaisance Revocable Trust, 10,786 shares through family entities, and 18,544 shares through CorLyst, LLC.
• Young also directly owns 124,500 warrants with an exercise price of $0.65, expiring on January 29, 2030, and 62,250 warrants with the same terms.

Sentiment

Score: 5

Explanation: This is a routine regulatory filing, so the sentiment is neutral. It simply reports changes in ownership.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing allows investors to track the ownership trends of key personnel at Processa Pharmaceuticals.

Stakeholder Impact

• The filing provides transparency to shareholders regarding the ownership of Processa Pharmaceuticals by its executives.

Key Dates

Keywords

Form 4, Beneficial Ownership, Processa Pharmaceuticals, David Young, PCSA, Warrants, Stock